Guerbet : Feedback réunion d’analystes : Clariscan va encore concentrer les préoccupations, courant 2019
>En bonne route sur son plan Gear 2023 mais avec certaines incertitudes - Au-delà de la présentation des chiffres 2018, commentés hier, le management a concentré son exposé sur i/ les espoirs fondés sur, le successeur de Dotarem®, gadopiclenol (forte relaxivité, protocole de Ph.III solidement validé par l’EMEA et la FDA semble-t-il, seule molécule en R&D en IRM), ii/ le début de la commercialisation des produits d’Accurate (cathéters) déjà approuvés et vendus aux USA ...Guerbet is a French pharmaceutical group that develops, markets, and provides maintenance services for medical equipment and devices destined for diagnostic and interventional imaging. Co.'s portfolio comprises media solutions covering MRI, X-rays and products devoted to International Radiology and Theranostics and medical devices. Co. organizes its operation by product family covering Magnetic Resonance Imaging (MRI), X-rays (XR) and Interventional Radiology and Theranostics (IRT). The MRI family includes Dotarem® and Artirem®; Co.'s X-ray product family includes Xenetix®, Optiray®/Optiject®, Oxilan®, and Telebrix®; and the IRT product family has Lipiodol®, Bleu Patente V and Hexabrix®.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.